Wednesday, July 26, 2017

Enter Title

A word from the PHSANZ President.
View this email in your browser

Good News & Bad News from the PBAC.

On Friday August 22nd the PBAC published two recommendations that are of interest to the PHT community.

1) The Actelion submission to have the continuation rules for PAH therapies rationalised in order to allow continued access to therapy for patients after a decline of 20% in 6MWD was successfully recommended. Click here to download a full copy of the PBAC recommendation.

This is an important change. If a patient has not reached discontinuation criteria at the six month mark (first re-prescription) then a subsequent 20% fall in composite 6MWT, Echocardiographic and RHC endpoints will not require discontinuation and switch. We thank Actelion in their efforts to allow us to practice more efficiently and more in concordance with international guidelines.

2) The PBAC made a positive recommendation for the listing of Riociguat for the treatment of PAH in March 2014 (not currently PBS listed). A recent resubmission by the sponsor, Bayer, for a further recommendation for the treatment of patients with CTEPH was unfortunately deemed not successful in the latest PBAC publication.

The PBAC accepted that Riociguat was efficacious in inoperable CTEPH and persistent post PEA CTEPH but was concerned regarding the precision of the cost effectiveness estimates. We thank Bayer for their continued efforts for this patient group. 

Full details of this decision can be downloaded by clicking here

Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.

Our mailing address is:

unsubscribe from this list    update subscription preferences 

Copyright 2011 by PHSANZ